Synthonix was founded to fill a perceived need in the marketplace for molecules for drug discovery. While there are many molecules available in the marketplace, highly functionalized heterocycles have been difficult to find. Most molecules are simple variations of substituted benzene rings. Our aim is to fill the need for highly versatile compounds that enable chemists to synthesize high impact target molecules that are devoid of metabolic liabilities.


Synthonix specializes in the synthesis of building blocks and synthons that allows for chemical diversification for hit-to-lead, fragment based design, focused library synthesis, and lead optimization.
Our powerful molecules are tailored to participate in proven chemical reactions such as Suzuki and Stille coupling, condensations, cycloadditions, and many others.
Our team of scientists have spent many years developing our product range and have extensive experience in the chemistries in which they are used.
Please do not hesitate to call to speak with one of our researchers.
We are here to help you in your efforts.

Our products are manufactured at our 10,000 sq. ft. Wake Forest, NC facility.
We are located only minutes away from Research Triangle Park and from RDU airport.


We guarantee all of our products.
All products are rigorously analyzed for identity and purity.
If you have any problems with our products, we will replace the item or refund the cost.

Cofounder, President and CEO









Dr. Gary Allred is Cofounder, President and CEO of Synthonix Corporation. In addition to his extensive chemical and pharmaceutical expertise, Dr. Allred has over 15 years of experience in business development and management, intellectual property development, patent filing and prosecution, strategic and portfolio planning, contract negotiation, technology assessment, and competitive intelligence. Before co-founding Synthonix Corporation in 2003, Dr. Allred founded a successful startup in 1997 where he served as President and CEO. Prior to this he received his Ph.D. in organic chemistry from Emory University under Dr. Lanny Liebeskind. Dr. Allred performed research in copper-mediated and palladium-catalyzed coupling reactions, boron chemistry, and silane chemistry. He authored several papers in peer-reviewed journals and is an inventor of seven patents.






Cofounder, Vice President











Jonathan Scoggins is the co-founder of Synthonix Inc. He currently serves as Vice President of Synthonix. Jonathan has over 12 years of experience in the custom chemical business. Jonathan’s main focus with Synthonix is business management and business development. Before co-founding Synthonix Inc. Jonathan founded Ryscor Science Inc in 1998 where he served as President and CEO until starting Synthonix in 2003. Ryscor Science was a specialty chemical company that specialized in boronic acids as well as other boron containing compounds used in various areas of medicinal research and development. When Ryscor Science was formed the core focus was supplying boron-10 labeled amino acids for use in BNCT (boron neutron capture therapy) which was and still is a promising therapy for use on various types of malignant brain tumors. Jonathan received his undergraduate degree from North Carolina State University in 1996.




Vice President of Science and Technology



Phone: 215.264.2570
E-mail: jmelamed@synthonix.com
Regional Office:
3805 Old Easton Road
Doylestown, PA 18902




Dr. Jeffrey Y. Melamed, Vice President of Science and Technology at Synthonix, has recently joined the company and is currently involved with various aspects of the company including the design of metabolically robust molecules for drug industry chemists. Previously, Jeffrey Melamed was a medicinal chemist at Merck. During his twelve years at Merck Jeffrey focused much of his research on anti-viral and neuroscience targets which has given him experience with the design of a broad range of molecules. While at Merck he was the recipient of the MRL 2007 Special Achievement Award for designing and synthesizing the key compound that led to a no-go decision for the project team. In addition, he and his group focused on the synthesis of compounds that were designed to mitigate metabolic liabilities, improve solubility properties, and increase blood-brain barrier penetration using a data-driven design strategy. Over the last four years, Jeffrey was a participating member of a committee at Merck that was involved in designing high-impact, novel building blocks and scaffolds. These structures are highly valuable to Merck and they have become fundamental components in the development of preclinical and clinical candidates.